FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969644543> ?p ?o ?g. }

• W1969644543 abstract "Phosphoinositide 3-kinase (PI3K)-activated signalling has a critical role in the evolution of aggressive tumourigenesis and is therefore a prime target for anticancer therapy. Previously we have shown that the β galactoside binding protein (βGBP) cytokine, an antiproliferative molecule, induces functional inhibition of class 1A and class 1B PI3K. Here, we have investigated whether, by targeting PI3K, βGBP has therapeutic efficacy in aggressive breast cancer cells where strong mitogenic input is fuelled by overexpression of the ErbB2 (also known as HER/neu, for human epidermal growth factor receptor 2) oncoprotein receptor and have used immortalised ductal cells and non-aggressive mammary cancer cells, which express ErbB2 at low levels, as controls. Aggressive BT474 and SKBR3 cancer cells where ErbB2 is overexpressed, MCF10A immortalised ductal cells and non-invasive MCF-7 cancer cells which express low levels of ErbB2, both in their naive state and when forced to mimic aggressive behaviour, were used. Class IA PI3K was immunoprecipitated and the conversion of phosphatidylinositol (4,5)-biphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) assessed by ELISA. The consequences of PI3K inhibition by βGBP were analysed at proliferation level, by extracellular signal-regulated kinase (ERK) activation, by akt gene expression and by apoptosis. Apoptosis was documented by changes in mitochondrial membrane potential, alteration of the plasma membrane, caspase 3 activation and DNA fragmentation. Phosphorylated and total ERK were measured by Western blot analysis and akt mRNA levels by Northern blot analysis. The results obtained with the BT474 and SKBR3 cells were validated in the MCF10A ductal cells and in non-invasive MCF-7 breast cancer cells forced into mimicking the in vitro behaviour of the BT474 and SKBR3 cells. In aggressive breast cancer cells, where mitogenic signalling is enforced by the ErbB2 oncoprotein receptor, functional inhibition of the catalytic activity of PI3K by the βGBP cytokine and loss of akt mRNA results in apoptotic death. A functional correlation between ERK and the kt gene was also found. The relationship between ERK, akt mRNA, PI3K and cell vulnerability to βGBP challenge was sustained both in mammary ductal cells forced to mimic an aggressive behaviour and in non-aggressive breast cancer cells undergoing an enforced shift into an aggressive phenotype. βGBP, a newly discovered physiological inhibitor of PI3K, is a selective and potent inducer of apoptosis in aggressive breast cancer cells. Due to its physiological nature, which carries no chemotherapeutic disadvantages, βGBP has the potential to be safely tested in clinical trials." @default.
• W1969644543 created "2016-06-24" @default.
• W1969644543 creator A5021878839 @default.
• W1969644543 creator A5027267308 @default.
• W1969644543 date "2009-01-08" @default.
• W1969644543 modified "2023-10-16" @default.
• W1969644543 title "Phosphoinositide 3-kinase targeting by the β galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death" @default.
• W1969644543 cites W1529396499 @default.
• W1969644543 cites W1585517331 @default.
• W1969644543 cites W1601571585 @default.
• W1969644543 cites W19669284 @default.
• W1969644543 cites W1967647822 @default.
• W1969644543 cites W1968372807 @default.
• W1969644543 cites W1970694857 @default.
• W1969644543 cites W1980952363 @default.
• W1969644543 cites W1983313933 @default.
• W1969644543 cites W1984621921 @default.
• W1969644543 cites W1997469666 @default.
• W1969644543 cites W2017339970 @default.
• W1969644543 cites W2024357798 @default.
• W1969644543 cites W2029307764 @default.
• W1969644543 cites W2046425687 @default.
• W1969644543 cites W2054607545 @default.
• W1969644543 cites W2057458801 @default.
• W1969644543 cites W2060531515 @default.
• W1969644543 cites W2080719056 @default.
• W1969644543 cites W2081994535 @default.
• W1969644543 cites W2083604274 @default.
• W1969644543 cites W2085483616 @default.
• W1969644543 cites W2087861588 @default.
• W1969644543 cites W2091285777 @default.
• W1969644543 cites W2093295719 @default.
• W1969644543 cites W2099019742 @default.
• W1969644543 cites W2105349448 @default.
• W1969644543 cites W2107614388 @default.
• W1969644543 cites W2117263216 @default.
• W1969644543 cites W2121627701 @default.
• W1969644543 cites W2129172946 @default.
• W1969644543 cites W2147110251 @default.
• W1969644543 cites W2167010784 @default.
• W1969644543 cites W2168770561 @default.
• W1969644543 cites W2170839629 @default.
• W1969644543 cites W2388163742 @default.
• W1969644543 cites W4240237951 @default.
• W1969644543 doi "https://doi.org/10.1186/bcr2217" @default.
• W1969644543 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2687705" @default.
• W1969644543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19133120" @default.
• W1969644543 hasPublicationYear "2009" @default.
• W1969644543 type Work @default.
• W1969644543 sameAs 1969644543 @default.
• W1969644543 citedByCount "15" @default.
• W1969644543 countsByYear W19696445432012 @default.
• W1969644543 countsByYear W19696445432013 @default.
• W1969644543 countsByYear W19696445432014 @default.
• W1969644543 countsByYear W19696445432015 @default.
• W1969644543 countsByYear W19696445432017 @default.
• W1969644543 countsByYear W19696445432019 @default.
• W1969644543 countsByYear W19696445432020 @default.
• W1969644543 countsByYear W19696445432021 @default.
• W1969644543 countsByYear W19696445432023 @default.
• W1969644543 crossrefType "journal-article" @default.
• W1969644543 hasAuthorship W1969644543A5021878839 @default.
• W1969644543 hasAuthorship W1969644543A5027267308 @default.
• W1969644543 hasBestOaLocation W19696445431 @default.
• W1969644543 hasConcept C121608353 @default.
• W1969644543 hasConcept C153911025 @default.
• W1969644543 hasConcept C184235292 @default.
• W1969644543 hasConcept C191560914 @default.
• W1969644543 hasConcept C203014093 @default.
• W1969644543 hasConcept C204232928 @default.
• W1969644543 hasConcept C2778148616 @default.
• W1969644543 hasConcept C2779251935 @default.
• W1969644543 hasConcept C2781322055 @default.
• W1969644543 hasConcept C2994423619 @default.
• W1969644543 hasConcept C502942594 @default.
• W1969644543 hasConcept C54355233 @default.
• W1969644543 hasConcept C57074206 @default.
• W1969644543 hasConcept C62478195 @default.
• W1969644543 hasConcept C75217442 @default.
• W1969644543 hasConcept C86554907 @default.
• W1969644543 hasConcept C86803240 @default.
• W1969644543 hasConcept C95444343 @default.
• W1969644543 hasConcept C96232424 @default.
• W1969644543 hasConceptScore W1969644543C121608353 @default.
• W1969644543 hasConceptScore W1969644543C153911025 @default.
• W1969644543 hasConceptScore W1969644543C184235292 @default.
• W1969644543 hasConceptScore W1969644543C191560914 @default.
• W1969644543 hasConceptScore W1969644543C203014093 @default.
• W1969644543 hasConceptScore W1969644543C204232928 @default.
• W1969644543 hasConceptScore W1969644543C2778148616 @default.
• W1969644543 hasConceptScore W1969644543C2779251935 @default.
• W1969644543 hasConceptScore W1969644543C2781322055 @default.
• W1969644543 hasConceptScore W1969644543C2994423619 @default.
• W1969644543 hasConceptScore W1969644543C502942594 @default.
• W1969644543 hasConceptScore W1969644543C54355233 @default.
• W1969644543 hasConceptScore W1969644543C57074206 @default.
• W1969644543 hasConceptScore W1969644543C62478195 @default.
• W1969644543 hasConceptScore W1969644543C75217442 @default.
• W1969644543 hasConceptScore W1969644543C86554907 @default.
• W1969644543 hasConceptScore W1969644543C86803240 @default.

• next